Andrea Eleazar, MHS

US cancer deaths keep falling as lung cancer declines; smoking drops, screening rises, but rural and low-education gaps persist.

Advisory panel backs Galleri blood test for adults 50+, citing strong specificity, mixed sensitivity, and follow-up impacts as FDA weighs approval.

New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.

New 177Lu-dotatate radioligand therapy expands options for SSTR+ GEP-NETs, backed by NETTER-1 efficacy and key safety guidance.

Community oncology practices rapidly adopt bispecific therapy, but reimbursement gaps, intensive monitoring demands, and limited hospital coordination hinder safe, scalable in-office programs.

Real-world ESAS data show higher symptom burden after cancer diagnosis shifts spending from treatment to ER, home and mental health care.

Jeff Sharman, MD, explores how targeted therapies have transformed CLL treatment and what emerging approaches could shape the future of care.

CELESTIMO trial shows mosunetuzumab plus lenalidomide boosts PFS in relapsed follicular lymphoma, supporting earlier-line outpatient, chemo-free care.

FDA clears Triton 1 robotic colonoscopy for screening and advanced therapy, backed by first-in-human data showing high detection rates and reduced clinician workload.

Phase 3 trial shows trastuzumab botidotin boosts PFS and response rates vs T-DM1 in pretreated HER2-positive metastatic breast cancer, with manageable ocular toxicity.

KEYNOTE-D46 shows sacituzumab govitecan plus pembrolizumab misses PFS/OS targets in PD-L1–high metastatic NSCLC, despite higher responses and toxicity.

New RASolute trials test daraxonrasib for metastatic and resected pancreatic cancer, comparing combos and follow-up use to improve outcomes.

Jeff Sharman, MD, discusses bispecific antibodies, CAR T-cell therapy, and targeted agents reshaping non-Hodgkin lymphoma treatment.

ARROS-1 data show zidesamtinib drives 94% responses in untreated ROS1+ NSCLC, including brain metastases, supporting first-line FDA filing.

NHIS analysis reveals major screening gaps for disabled adults—especially self-care limits—while at-home stool tests boost colorectal screening access.

INBRX-106 plus pembrolizumab boosts response rates in first-line PD-L1–positive head and neck cancer, with striking benefits in HPV-positive patients and manageable side effects.

Purpose-built, decentralized oncology trials bring new therapies to community clinics, expanding access and showing trials aren’t just a last resort.

Mipletamig plus venetoclax and azacitidine delivers 93% clinical benefit in TP53-mutated frontline AML, fueling hopes for a new option.

U.S. alcohol-linked cancer deaths double since 1990, led by surging liver cancer; men, older adults hit hardest, with wide state-by-state gaps.

Next-gen T‑cell immunotherapies tackle resistance and expand access, as bispecifics, trispecifics, and off‑the‑shelf or in vivo CAR T-cell therapies move earlier.

ALINA trial shows adjuvant alectinib after ALK+ lung cancer surgery improves quality of life, with manageable safety and durable DFS.

Phase 3 Neo-Healer shows anbenitamab plus HB1801 boosts complete response rates in ERBB2-positive breast cancer, with manageable safety.

Ivonescimab extends survival and doubles PFS vs pembrolizumab in first-line PD‑L1+ metastatic NSCLC, with manageable safety.

A new CIRI2-CLL model uses MRD and clinical data to better predict CLL survival after fixed-duration therapy, enabling personalized risk stratification.

FDA grants breakthrough status to JBS-003 F-MISO PET imaging, aiming to personalize radiation in HPV-positive throat cancer by safely reducing dose for nonhypoxic tumors.

Phase 3 SANOVO shows savolitinib plus osimertinib extends PFS in first-line EGFR-mutant, MET-high NSCLC, hinting at OS gains.

Learn how oncologists spot burnout early and cut it with smarter workflows, PTO coverage, supportive leadership, and AI-powered documentation.

FDA aligns on IDE849 phase 3 trial in post-tarlatamab ES-SCLC, testing DLL3 ADC vs chemo, aiming for accelerated approval.

Phase 2 data show an outpatient fixed-duration combo yields 79% complete responses and 18.6-month PFS in relapsed mantle cell lymphoma.

FDA issues third CRL for lower-dose dasatinib Dasynoc over manufacturing, not data, as Xspray races to resubmit amid PPI absorption benefits.